Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Necrosis Factor Ligand Superfamily Member 8 (TNFSF8)
- Target
- TNFSF8
- Molecular classification
- Type II transmembrane glycoprotein, Tumor necrosis factor ligand superfamily member, Ligand
01
Overview
CD30 Ligand (CD30L), also known as TNFSF8 or CD153, is a type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) ligand superfamily. It is primarily expressed on activated T cells, B cells, monocytes/macrophages, and certain dendritic cells. CD30L binds to its receptor, CD30 (TNFRSF8), to mediate a range of immunological effects, including cell proliferation, differentiation, and apoptosis. The CD30/CD30L axis plays a significant role in Hodgkin lymphoma and other hematopoietic malignancies, as well as inflammatory diseases, making it a therapeutic target. There is evidence for reverse signaling.
- Other names
- CD30 LigandCD30LCD153
02
Mechanism of action
Binding to CD30/TNFRSF8, activating NFκB and MAPK pathways, influencing proliferation, survival, and apoptosis.
03
Biological functions
Cell proliferationCell differentiationApoptosisCytokine productionImmune responseT-cell costimulationB-cell growth/differentiationSignal transduction
04
Disease associations
Hodgkin lymphomaAnaplastic large-cell lymphomaOther hematopoietic malignanciesInflammatory diseases
05
Safety considerations
Potential for immune-related adverse events due to modulation of immune responses.
06
Interacting drugs
Antibody-drug conjugates (targeting CD30/CD30L axis)
07
Biomarkers
CD30L expression in lymphomas
Beyond the preview
Go deeper on Tumor Necrosis Factor Ligand Superfamily Member 8 (TNFSF8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor Necrosis Factor Ligand Superfamily Member 8 (TNFSF8).